Please login to the form below

Not currently logged in
Email:
Password:

New Accounts, February, 2009 - PR & Med Ed

New pharmaceutical account wins notified to us by the winning agency for the period December 2008 to January 2009 inclusive

New pharmaceutical account wins notified to us by the winning agency for the period December 2008 to January 2009 inclusive:

 

CLIENT

PRODUCT

THERAPEUTIC AREA

WINNING AGENCY

AstraZeneca RECENTIN Recurrent glioblastoma multiforme and colorectal cancer IMC Medical Communication
AstraZeneca ZD4054 Prostate cancer IMC Medical Communication
Baxter Europe Advate and FEIBA Haemophilia Ashley Communications
Roche Pegasys Hepatitis C and B Ketchum
Sanofi-aventis/ Bristol-Myers Squibb n/a Cardiovascular Medaxial
SPD Development Company Clearblue digital pregnancy test with conception indicator Women's health IMC Medical Communication
Typharm Dermatology portfolio Dermatology echo
TOPRA Corporate n/a Ash Healthcare
 Wyeth  ReFacto Haemophilia ROAD 

  

Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may not be involved with some of the products listed in other ways, or in domestic, overseas or international markets.

To submit an entry for New Accounts, email new_accounts@pmlive.com

5th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics